Background: Ascites and pleural effusion are well recognized complications of pancreatic diseases. Drug therapy of these is limited by high cost, prolonged hospitalization and failure rates ...

Rein also provided an update on its pipeline, highlighting LTI-01, a Phase 2b-ready therapy for loculated pleural effusions, which holds Orphan Drug Designation for pleural empyema. Brian Windsor ...

LTI-01 : The Company's Phase 2b-ready asset is a first-in-class therapy for the treatment of loculated pleural effusions (LPEs). It holds Orphan Drug Designation for the treatment of pleural ...

LTI-01: The Company's Phase 2b-ready asset is a first-in-class therapy for the treatment of loculated pleural effusions (LPEs). It holds Orphan Drug Designation for the treatment of pleural empyema in ...

"Our rebrand to Rein Therapeutics reflects our unwavering commitment to address the critical needs of underserved patients with fibrotic diseases," said Brian Windsor, Ph.D., President and Chief ...

The clinical diagnosis of acute pericarditis is based on simple criteria: typical chest pain, pericardial friction rub (Figure 2), widespread ST-segment elevation (Figure 3) and pericardial ...

After hours: January 10 at 5:58:33 PM EST Loading Chart for ALRN ...

AUSTIN, Texas, Jan. 10, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a ...

"Our rebrand to Rein Therapeutics reflects our unwavering commitment to address the critical needs of underserved patients with fibrotic diseases," said Brian Windsor, Ph.D., President and Chief ...